A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys)180 microg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B.

Trial Profile

A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys)180 microg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms PADD-ON
  • Most Recent Events

    • 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Apr 2016 Results of interim analysis at week 24 (n=137) as well as safety data (n=160) presented at The International Liver Congress™ 2016.
    • 01 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top